National Guidelines for Cervical Cancer Prevention and Control

Objectives

Provide Jamaica’s national best-practice framework for cervical cancer prevention and control, standardising public-health practice to increase screening, detect abnormalities before clinical presentation, treat or refer pre-cancerous disease, and prevent cervical cancer deaths.[1][2][3]The clinical aims are to cure cancer where possible, prolong useful life, improve quality of life and support rehabilitation.[4]

• Strengthen organised Pap smear screening, particularly among women aged 25 to 54 years and those who have not been screened, because early detection and treatment can prevent progression to cervical cancer.[5][6]
• Promote screening at least every three years as a core prevention measure, while recognising that well-organised screening programmes can substantially reduce cervical cancer incidence and mortality.[3][7]
• Identify and manage pre-cancerous cervical changes, including through repeat testing, colposcopy, excisional or ablative treatment, specialist referral and follow-up.[2][8]
• Address persistent human papillomavirus infection and recognised associated risks, including smoking, immune suppression, hormonal contraceptive use, high parity and a higher number of lifetime sexual partners.[3][5]
• Apply screening and management standards across routine services and special circumstances, including pregnancy, hysterectomy, HIV infection, immunosuppression, older unscreened women and abnormal cytology.[9][7]
• Ensure that suspected or confirmed invasive disease receives timely diagnostic assessment, staging, appropriate therapy and specialist hospital care.[10][4]

Implementation

Deliver prevention and control through a standardised pathway spanning community and facility-based screening, specimen collection and laboratory processing, result communication, recall, referral, treatment and follow-up.[2][8][7]The guidance is associated with the Ministry of Health and its Health Promotion and Protection Division, is approved by the Director of Health Promotion and Protection, and draws on contributions from the Jamaica Cancer Society, National Family Planning Board, hospitals, the University Hospital of the West Indies, Victoria Jubilee Hospital and the National Public Health Laboratory.[1][6]

• Provide screening through health clinics and centres, hospitals, private physicians’ offices, the Jamaica Cancer Society, satellite clinics, outreach programmes, workplace services, health fairs and mobile units.[8]Distribute the guidance to Type I, II, III, IV and V health centres and all hospitals.[5]
• Initiate screening within three years of commencing sexual activity, while not routinely screening women under 18 years of age.[5]Offer annual Pap smears unless otherwise indicated, then screen women aged 25 to 54 years every three years after two consecutive normal results, continuing to age 65.[5]Discontinue at age 65 only where the specified satisfactory screening history is met, and require previously unscreened older women to have three documented normal annual smears before stopping.[5]
• Increase screening frequency for women with HIV infection or weakened immunity, including annual screening and lifelong screening for immunosuppressed women.[5][9]Continue routine-interval smears after subtotal hysterectomy, avoid screening after total hysterectomy for benign disease without dysplasia history, and use vaginal vault smears after specified high-grade or radical hysterectomy indications.[9]
• Prepare clients through explanation, education and counselling; complete the cytology request form; take the Pap smear before digital vaginal examination; and give clients a six-week return date.[9][11]Protect confidentiality and educate clients and family members before referral where appropriate.[8][7]
• Maintain specimen quality by using appropriate collection materials, matching slide labels to registration forms, sampling the ectocervix through full rotation with an Ayre spatula, obtaining endocervical and squamous cells where possible, promptly fixing smears and dispatching them with request forms to the laboratory.[11]Prevent inadequate samples by avoiding air-drying, excessive smear thickness and excessive blood, and use the specified spray fixative or fresh 95% alcohol.[11]Use a spatula rather than a cytobrush during pregnancy.[9][11]
• Require providers to follow the National Guidelines for Cervical Cancer Screening, meet gynaecological examination requirements, ensure personnel are trained in sample collection and preservation, and arrange sterilisation of reusable equipment and safe storage of 95% alcohol where used.[7]
• Manage abnormal results according to severity through repeat testing, routine screening, gynaecological evaluation, colposcopy, specialist hospital care or treatment.[10]Refer HIV-positive women with cytology from atypical squamous cells of undetermined significance upwards for gynaecological assessment, and refer high-grade squamous intraepithelial lesions, cervical intraepithelial neoplasia grade II and specified abnormal findings for colposcopy.[9]
• Refer women with high-grade squamous intraepithelial lesions, atypical squamous cells where high-grade disease cannot be excluded, or glandular abnormalities for gynaecological evaluation within six weeks, and refer invasive cancer to hospital for specialist care.[10]Refer suspected invasive cervical cancer immediately to an oncologist or gynaecological clinic, maintain active follow-up and consider palliative care where necessary.[8]
• Use colposcopy for specified high-grade, persistent or repeated abnormalities, unexplained cervical lesions or bleeding, and atypical glandular cells.[4]Where colposcopy is unavailable, use cone biopsy for women who have completed childbearing.[4]During pregnancy, defer treatment for non-invasive high-grade disease until after delivery, avoid cervical biopsy during colposcopy as specified, and do not terminate pregnancy or require Caesarean delivery for pre-invasive disease.[10]
• Maintain results, recall, reminder and referral systems; process Pap smear results within a reasonable period, suggested as no more than three months; and verify that results have been received.[7]Document services, interventions and outcomes in the cervical cancer register, submit timely reports, and ensure referring facilities confirm attendance and maintain follow-up with specialist review when needed.[8]
• Adapt treatment choices to available human, physical and financial resources.[10][4]The source does not specify programme budgets, financing mechanisms, staffing plans, formal governance arrangements beyond the named directorate and institutions, or a comprehensive performance-indicator framework.[3][10][7]

Monitoring & Evaluation

Monitoring and accountability centre on recording screening, results, referrals, treatment and follow-up within a cervical cancer register, supported by timely reporting and confirmation that referred clients attend appointments.[8]The guidance also requires facilities to maintain recall, reminder and referral systems, verify that Pap smear results are received, and provide active follow-up after treatment.[8][7]

• Record client screening histories, smear adequacy and abnormal results to support clinical decisions, including whether screening may stop after age 65.[5]
• Document services, interventions and outcomes in the cervical cancer register, and monitor clients through their health facility after treatment.[8]
• Submit timely reports, confirm attendance following referral, and maintain follow-up through specialist review where required.[8]
• Process Pap smear results within a reasonable turnaround time, suggested as no more than three months after the smear is taken, and verify that results reach the relevant facility and client.[7]
• Recall clients for results and reminders, and maintain referral pathways for further assessment, colposcopy, treatment and specialist care.[8][7]
• Monitor specimen quality through consistent completion of patient information and matching of slide labels with registration forms.[9][11]
• Apply quality controls during sample preparation by avoiding air-drying, excessive smear thickness and excessive blood, using appropriate fixation, and dispatching specimens promptly to the laboratory.[11]
• Follow specified clinical review intervals, including repeat Pap smears for selected low-grade lesions every six months for two years, with return to the regular interval once all smears are negative and satisfactory.[8]
• Reassess women after colposcopy or delivery, repeat testing at specified intervals, and refer women after consecutive unsatisfactory smears.[10]

Screening coverage and frequency are presented as important operational considerations. Estimated reductions in cumulative cervical cancer rates are 93% with one- or two-year screening, 91% with three-year screening, 84% with five-year screening and 64% with ten-year screening.[5]The intended programme outcomes are increased screening rates, improved management of abnormal Pap smear results, earlier detection and treatment of pre-cancerous changes, and reduced cervical cancer mortality.[1][2][3]

Service standards apply to all facilities and individuals offering Pap smears, including requirements to follow national screening guidance, protect confidentiality, ensure trained personnel collect and preserve samples, and maintain systems for results, recalls, reminders and referrals.[7]Referrals should be supported by education and counselling, use established links between primary care and specialist services, and be followed by return to primary care where appropriate.[8]

Formal programme-level indicators, a defined evaluation schedule, a comprehensive surveillance system, explicit performance targets and detailed accountability procedures are not specified in the supplied text.[3][10][4]

Costing & Financing

No programme costs, budget allocations, funding sources, financing mechanisms, resource-mobilisation arrangements, funding gaps or economic assumptions are specified.[1][3][8][7][6][12]

• Provide the equipment and consumables needed for Pap smear collection, including slides, fixative, Ayre spatulas, specula, cotton and specimen transport materials, although no unit costs or procurement budget is given.[9][11]
• Ensure access to trained personnel, laboratory processing, sterilisation arrangements for reusable equipment, safe storage of 95% alcohol where used, referral services, colposcopy and treatment capacity, without specifying the resources required or their financing.[4][7]
• Determine the treatment approach in relation to available human, physical and financial resources, but without setting out resource thresholds, affordability assessments or allocation criteria.[10][4]
• Support delivery through health centres, hospitals, private physicians' offices, the Jamaica Cancer Society, satellite clinics, outreach programmes, workplace services, health fairs and mobile units; associated operating costs are not specified.[8]